Marie-France Tschudin, head of Novartis subsidiary AAA, takes over from Paul Hudson as Novartis Pharma CEO
Novartis has said Marie-France Tschudin will take over from Paul Hudson as the head of Novartis Pharmaceuticals.
The announcement comes after French firm Sanofi said that Paul Hudson, the current chief executive of Novartis Pharmaceuticals, will succeed Olivier Brandicourt as the company’s new CEO.
Marie-France Tschudin, currently the head of Novartis subsidiary Advanced Accelerator Applications (AAA), will in her new role report to Novartis CEO Vas Narasimhan as she joins the Executive Committee with immediate effect.
Tschudin brings to the role more than 25 years of pharmaceutical industry and biotech experience having worked in a number of major firms. Having graduated from Georgetown University in 1993, Tschudin joined Janssen-Cilag the following year.
The experienced pharma exec later took roles of increasing superiority at firms including Celgene and Schering-Plough before joining Novartis in 2017. Tschudin speaks six languages and holds an MBA from the Institute for Management Development (IMD) business school in Lausanne, Switzerland.
Vas Narasimhan commented: “I am pleased that Marie-France Tschudin is ready to take over from Paul Hudson to further grow the business and lead the expected upcoming launches of our transformative medicines.”
“Marie-France has a strong record of accomplishments in driving commercial excellence and a culture of inclusiveness and integrity founded on her exemplary commitment to patients and customers. She has always been highly respected by people working with her and will bring new and diverse perspectives to our executive leadership team.”
“I would like to thank Paul for his exceptional leadership in positioning our pharmaceuticals business for strong future growth. He also established a new culture of commercial excellence, integrity and nurtured a strong, diverse talent pool.”
Commenting on her own appointment, Tschudin said: “I’m honoured and excited to be given the opportunity to lead and further develop one of the greatest businesses in our industry. I would like to thank Paul for his leadership and his focus on people and I wish him continued success going forward. I’m excited to deliver my part in reimagining medicine for as many people as possible together with our associates at Novartis.”